Nanoparticle-mediated drug delivery system for pulmonary arterial hypertension

Kazufumi Nakamura, Hiromi Matsubara, Satoshi Akagi, Toshihiro Sarashina, Kentaro Ejiri, Norifumi Kawakita, Masashi Yoshida, Toru Miyoshi, Atsuyuki Watanabe, Nobuhiro Nishii, Hiroshi Ito

Research output: Contribution to journalReview articlepeer-review

15 Citations (Scopus)

Abstract

Nanoparticles have been used as a novel drug delivery system. Drug-incorporated nanoparticles for local delivery might optimize the efficacy and minimize the side effects of drugs. The efficacy and safety of intratracheal administration of prostacyclin analog (beraprost) -incorporated nanoparticles and imatinib (a PDGF-receptor tyrosine kinase inhibitor) -incorporated nanoparticles in Sugen-hypoxia-normoxia or monocrotaline rat models of pulmonary arterial hypertension (PAH) and in human PAH-pulmonary arterial smooth muscle cells have been reported. The use of inhaled drug-incorporated nanoparticles might be a novel approach for the treatment of PAH.

Original languageEnglish
Article number48
JournalJournal of Clinical Medicine
Volume6
Issue number5
DOIs
Publication statusPublished - May 2017

Keywords

  • Drug delivery system
  • Nanoparticle
  • Prostacyclin
  • Pulmonary arterial hypertension

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Nanoparticle-mediated drug delivery system for pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this